Marcus Q Bernardini
Overview
Explore the profile of Marcus Q Bernardini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
2138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chung D, Shakfa N, Vakharia J, Warner K, Jacquelot N, Sayad A, et al.
Cancer Immunol Res
. 2025 Mar;
:OF1-OF20.
PMID: 40084939
Immunotherapies have had unprecedented success in the treatment of multiple cancer types, albeit with variable response rates. Unraveling the complex network of immune cells within the tumor microenvironment (TME) may...
2.
Hogen L, Siriwardena T, Salman L, Bernardini M, Ferguson S, Laframboise S, et al.
Int J Gynecol Cancer
. 2025 Feb;
:101640.
PMID: 39955188
Objective: This study aimed to identify factors influencing the decision to perform diverting ileostomy during cytoreductive surgery with colon resection for advanced ovarian cancer and investigate the associated complications and...
3.
Kim S, Oldfield L, Kim R, Espin-Garcia O, Han K, Vicus D, et al.
J Surg Oncol
. 2024 Nov;
PMID: 39501493
Background And Objectives: Adoption of molecular classification in endometrial cancer (EC) into clinical practice remains challenging due to complexity in coordination of multiple assays. We aimed to develop a simple...
4.
Ramirez P, Robledo K, Frumovitz M, Pareja R, Ribeiro R, Lopez A, et al.
J Clin Oncol
. 2024 May;
42(23):2741-2746.
PMID: 38810208
JCO The aim of this study was to compare overall survival between open and minimally invasive radical hysterectomy with participants followed for 4.5 years. The primary objective was to evaluate...
5.
Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors
Chung D, Ghaedi M, Warner K, Sayad A, Saibil S, Bernardini M, et al.
Oncoimmunology
. 2024 May;
13(1):2349347.
PMID: 38746870
The innate lymphoid cell (ILC) family is composed of heterogeneous innate effector and helper immune cells that preferentially reside in tissues where they promote tissue homeostasis. In cancer, they have...
6.
Dareng E, Coetzee S, Tyrer J, Peng P, Rosenow W, Chen S, et al.
Am J Hum Genet
. 2024 May;
111(6):1061-1083.
PMID: 38723632
To identify credible causal risk variants (CCVs) associated with different histotypes of epithelial ovarian cancer (EOC), we performed genome-wide association analysis for 470,825 genotyped and 10,163,797 imputed SNPs in 25,981...
7.
Chung D, Garcia-Batres C, Millar D, Wong S, Elford A, Mathews J, et al.
J Immunol
. 2024 Apr;
212(12):1904-1912.
PMID: 38668728
NK cells have been shown to exhibit inflammatory and immunoregulatory functions in a variety of healthy and diseased settings. In the context of chronic viral infection and cancer, distinct NK...
8.
Kim S, Parbhakar A, Li X, Bernardini M, Hogen L, May T
Int J Gynecol Cancer
. 2024 Mar;
34(6):879-885.
PMID: 38548312
Objectives: Given the high response to platinum based chemotherapy in 1/2 mutated high grade serous ovarian cancers, there is uncertainty about the relative benefits of primary cytoreductive surgery versus neoadjuvant...
9.
Sustainability of an enhanced recovery pathway after minimally invasive gynecologic oncology surgery
McCracken A, Kim R, Laframboise S, Maganti M, Bernardini M, Ferguson S, et al.
Int J Gynecol Cancer
. 2024 Mar;
34(5):738-744.
PMID: 38531541
Objective: Same day discharge is safe after minimally invasive gynecology oncology surgery. Our quality improvement peri-operative program based on enhanced recovery after surgery principles led to an increase in same...
10.
Wenk D, Khan S, Ignatchenko V, May T, Bernardini M, Kislinger T
J Proteome Res
. 2024 Jan;
23(2):749-759.
PMID: 38266179
High-grade serous ovarian carcinoma (HGSC) is the most prevalent subtype of epithelial ovarian cancer. The combination of a high rate of recurrence and novel therapies in HGSC necessitates an accurate...